RMTINasdaqPharmaceutical PreparationsFiscal year ends December 31
ROCKWELL MEDICAL, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.49+0.06 (+0.81%)
Close on Oct 19, 2026
- Market cap
- $29.65M
- P/E (TTM)
- –
- Dividend yield
- –
ROCKWELL MEDICAL, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concentrate Product | – | – | – | $15.93M | $16.07M | $18.59M | $24.65M | $28.31M | $25.82M | $22.67M | $22.08M | $21.57M | – | – |
| Drug Revenues | – | – | – | $0 | $0 | $325.00K | $12.00K | $11.00K | $12.00K | $11.00K | $11.00K | $2.20M | – | – |
| Products Purchase Agreement | – | – | – | – | $300.00K | $900.00K | – | – | – | – | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $15.13M | $14.56M | $15.91M | $13.82M | $14.19M | $16.44M | $21.87M | $26.25M | $23.21M | $20.93M | $20.55M | $19.74M | 85.1% | +6.6% |
| Rest of World | $2.65M | $2.77M | $2.44M | $2.10M | $1.88M | $2.48M | $2.80M | $2.07M | $2.62M | $1.74M | $1.55M | $4.03M | 14.9% | +40.8% |
From the segment and revenue-disaggregation notes of Rockwell Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.